Polyethyleneimine:dna formulations for aerosol delivery
CA 2368185 A1 · Owner: Research Development Foundation · Inventors: Orson, Frank Mcnair; Kinsey, Berma M.; Densmore, Charles L. Jr.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention demonstrates that polycationic non-lipid:DNA , formulations are resistant to nebulizer-induced degradation and are much more specific and efficient than lipid-based formulations in transfecting respiratory tract tissues in vivo. Results presented herein demonstrate that polyethyleneimine (PEI) formulations are about 10-fold more effective than previous lipid-based formulations when delivered in vivo by jet nebulizer. Therefore, aerosolized polyethyleneimine-based formulations are provided herein for use in targeting gene therapy via the respiratory tract.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 31, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 31, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 31, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.